Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05087056 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
A Phase 2 study of Meningitis, Meningococcal, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 302
- Enrollment target
- 20
- Study locations
NCT05087056 is a Phase 2 study of Meningitis, Meningococcal that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 302 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT05087056, a Phase 2 study of Meningitis, Meningococcal, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 302 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT MenABCWY vaccine
Study Locations (20)
Nebraska
- GSK Investigational Site - Grand Island
- GSK Investigational Site - Lincoln
- GSK Investigational Site - Omaha
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Miami
Montana
- GSK Investigational Site - Missoula
- GSK Investigational Site - Missoula
New York
- GSK Investigational Site - Binghamton
- GSK Investigational Site - Endwell
Alabama
- GSK Investigational Site - Birmingham
Arizona
- GSK Investigational Site - Tucson
California
- GSK Investigational Site - Ventura
District of Columbia
- GSK Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 302 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2027-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05087056
The ClinicalTrials.gov registry entry for NCT05087056 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 302 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningitis, Meningococcal appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05087056 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Nebraska, Florida, Montana.
Frequently Asked Questions
What is clinical trial NCT05087056 about?
NCT05087056 is a clinical study titled "Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents". The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
What is the current status of trial NCT05087056?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 302 participants. The study started on 2021-11-18. Estimated completion is 2027-02-05.
What conditions does trial NCT05087056 study?
This clinical trial studies the following conditions: Meningitis, Meningococcal.
What interventions are being tested in trial NCT05087056?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), MenABCWY vaccine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05087056?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05087056 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningitis, Meningococcal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.